Cancer treatment leaves the immune system depleted, and recovery is real and measurable. Whether any therapy can improve on that recovery — or reduce the risk of recurrence — is a separate question, and the honest answer is short.
## ⚠️ Your oncology follow-up is not optional, and nothing here replaces any part of it
Keep every scheduled appointment, scan, tumour-marker test and clinical review. Surveillance schedules
exist because recurrence detected early is treatable and recurrence detected late often is not. **Missing
or delaying scheduled follow-up is one of the few decisions a survivor can make that measurably worsens
outcomes.**
**No blood test, immune panel, infusion or cell therapy described on this page detects cancer, monitors for
recurrence, or substitutes for imaging, tumour markers or oncology review.**
⚠️ **There is no clinical evidence that stem cell therapy, exosome therapy or NK/NKT cell infusion reduces
the risk of cancer recurrence.** We searched for it specifically. No trial, no cohort study, no
meta-analysis. If anyone tells you otherwise, ask them for the trial.
Contact your oncology team promptly about new or unexplained lumps, pain, weight loss, persistent
fatigue that is worsening rather than improving, night sweats, or any symptom resembling your original
presentation.
What "Surveillance" Actually Means
In oncology, surveillance is a defined programme: scheduled imaging, tumour markers where they apply, physical examination, and clinical review at intervals set by your cancer type, stage and treatment. It exists to find recurrence at a point when it can still be treated.
⚠️ On wellness and clinic websites, the same word is often used for an immune blood panel or an infusion. These are not the same activity. An NK cell count tells you something about your immune system. It tells you nothing about whether you have cancer.
Minimal residual disease (MRD) monitoring is also a specific, validated laboratory technique — flow cytometry, PCR or next-generation sequencing for defined disease markers, established in particular haematological cancers. A general immune function panel is not MRD monitoring, and no product described on this page provides it.
Surveillance matters because recurrence is a leading cause of death among people who have survived cancer — established most clearly in long-term follow-up of five-year survivors of childhood cancer, where recurrence of the original disease is a principal cause of late mortality alongside second cancers and cardiac late effects [1]. ⚠️ That cohort is children, and adult survivorship has a different mortality structure; the general point that surveillance exists to catch treatable recurrence holds across both.
Conventional surveillance does have real limitations: imaging requires a substantial cell mass before a lesion is detectable, tumour markers can lag behind disease, and repeated CT carries cumulative radiation exposure. Those limitations are reasons for research, not reasons to substitute something unvalidated.
What Your Survivorship Care Plan Already Does
This section comes first because the evidence here is stronger than anything else on this page — by a wide margin.
Exercise
Systematic review and meta-analysis of 136 studies [11]. Comparing highest with lowest post-diagnosis
physical activity:
- Cancer-specific mortality: HR 0.63 (95% CI 0.53–0.75)
- All-cancers, pre-diagnosis activity: HR 0.82 (95% CI 0.79–0.86)
- Breast and colorectal cancer, post-diagnosis: HR 0.58–0.63
- An inverse dose–response relationship, with the steepest reductions up to about 10–15 MET-hours per week
Benefits held across most subgroups examined — sex, BMI, menopausal status, and activity domain.
The American College of Sports Medicine International Multidisciplinary Roundtable concluded that specific doses of aerobic training, resistance training, or both improve anxiety, depressive symptoms, fatigue, physical functioning and health-related quality of life in cancer survivors, and that exercise testing and training are generally safe for this population. Its headline recommendation is that every survivor should "avoid inactivity." [10]
⚠️ Read those two paragraphs against the rest of this page. The intervention with a mortality hazard ratio is also the intervention that improves fatigue and anxiety — the two symptoms that bring most survivors to a clinic like ours. It costs nothing.
The rest of the plan
Scheduled surveillance — the only thing that detects recurrence. Management of late effects — cardiac, endocrine, neuropathic, cognitive; these are common, specific to your treatment, and treatable. Nutrition and smoking cessation. Psychosocial support — see the section on fear of recurrence below, which is a real and prevalent problem with real interventions.
If you do not have a written survivorship care plan, ask your oncology team for one. It is the single most useful document you can hold.
The Immune Gap: What Is Genuinely Known
Chemotherapy and radiation act on rapidly dividing cells, including haematopoietic progenitors. Lymphocyte counts fall during treatment and recover over months, with T-cell reconstitution following distinct thymic-dependent and thymic-independent pathways — recovery is slower in adults, whose thymic function has declined [3].
The deficit is not only quantitative. NK cell cytotoxic function can remain impaired even when counts have normalised; reduced expression of activating receptors including NKG2D and CD161 has been associated with impaired NK cytotoxicity in cancer patients [4].
⚠️ What is not established is that this measurable deficit translates into recurrence risk that can be modified by treating the deficit. That step — from "immune function is lower" to "raising it prevents recurrence" — has never been demonstrated in a clinical trial.
NK and NKT Cells: Real Science, Correctly Scoped
The biology here is genuine and worth understanding.
NK cells kill abnormal cells without prior antigen presentation, recognising "missing self" — the loss of MHC class I that many tumours use to evade T cells [5]. NKT cells are CD1d-restricted, recognise lipid antigens, and produce large amounts of IFN-γ rapidly, activating both NK and cytotoxic T cells [6][7].
The cancer immunoediting framework describes how the immune system both suppresses tumours and shapes their evolution — supported by increased cancer incidence in immunosuppressed transplant recipients and by tumour rejection in immunocompetent but not immunodeficient animals [9]. There is direct evidence for the mechanism in humans: absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion [8].
Therapeutically, cytokine-induced memory-like NK cells show enhanced responses against myeloid leukaemia [21], and NK-cell-based approaches are an active and legitimate area of cancer immunotherapy [2].
### ⚠️ Where that evidence does and does not apply
All of the therapeutic work above involves **engineered, expanded, or cytokine-activated cells given as
cancer treatment, in clinical trials, largely in patients with active disease** — much of it in
haematological malignancy.
**None of it tests whether infusing expanded NK or NKT cells into a person in remission with no detectable
disease reduces their risk of recurrence.** That trial has not been done. Evidence that NK cells can attack
leukaemia in a treatment trial is not evidence that an NK infusion prevents recurrence in a well person.
MSCs: What They Actually Do
⛔ The mechanism runs the opposite way to the marketing
Mesenchymal stromal cells are used clinically in graft-versus-host disease and inflammatory conditions because they suppress immune responses.
MSCs *"exert broad immunosuppressive potential, modulating the activity of cells of innate and adaptive
immune systems." They secrete PD-L1 and PD-L2, and through them "suppress the activation of CD4+ T
cells, downregulate interleukin-2 secretion and induce irreversible hyporesponsiveness and cell death."* [15]
⚠️ PD-L1 and PD-L2 are the checkpoint ligands that cancer immunotherapy exists to block. Drugs such as pembrolizumab and nivolumab work by preventing PD-L1/PD-1 engagement so that T cells can attack tumours.
A therapy that secretes PD-L1 is doing what checkpoint inhibitors are prescribed to prevent. Whatever else MSCs may offer, they are not a plausible enhancer of anti-tumour immune surveillance, and anyone selling them to cancer survivors on that rationale has the mechanism backwards.
The tumour question, stated plainly
MSCs home to tumours. This is well established — it is the basis of research using MSCs as delivery vehicles to carry anti-cancer agents such as TRAIL into metastatic disease [16]. That same tropism is the reason for concern.
The concern is named in the safety literature, not invented by critics:
*"Although clinical application of mesenchymal stem cells has shown beneficial effects in the therapy of
autoimmune and chronic inflammatory diseases, **the ability to promote tumor growth and metastasis and
overestimated therapeutic potential of MSCs still provide concerns for the field of regenerative
medicine*." — and for stem-cell therapy generally, *"undesired differentiation and malignant
transformation are major safety issues."* [13]
The picture is genuinely mixed rather than uniformly negative. MSCs show context-dependent pro- and anti-tumour effects, varying with source, activation state and tumour microenvironment [19], and mesenchymal progenitor cells have inhibited tumour growth in some experimental systems [20].
"Context-dependent" is not reassurance. It means the outcome depends on conditions nobody can currently specify for an individual patient.
What the human safety data actually say
⚖️ The longest human follow-up available, and it cuts both ways. Thirty-one patients given MSCs for acute GVHD or haemorrhagic cystitis, followed for years [14]:
Reassuring:
"No increase in leukemia relapse or graft rejection was found."
This is the most direct human evidence on the question a survivor actually cares about, and it points the favourable way. The same study also found that MSCs from early culture passages (1–2) gave 75% one-year survival versus 21% for later passages (3–4), P < .01 — a real and important manufacturing finding.
Alarming:
**"Among patients recovering from aGVHD, 54% died of late infections, between 4 months and 2 years after
MSC treatment."** Infectious complications occurred years after recovery; cytomegalovirus viral load was
high and CMV disease was common.
⚠️ This is the risk that matters most for the reader of this page. If you are a survivor with persistent fatigue and frequent infections — the profile clinics recruit for — you are being offered an immunosuppressive therapy whose best-documented long-term harm in humans is death from late infection.
The animal evidence, described accurately
Studies frequently cited as safety reassurance are more limited than they appear. The most-cited found no tumour formation in Balb/c-nu nude mice over 26 weeks at high doses, no toxicity in SCID mice over 13 weeks, and — the human component — no serious adverse events in 8 men with spinal cord injury given a single IV dose, followed for 3 months [17].
⚠️ Not one cancer survivor, and three months cannot address recurrence. ⚠️ Nude and SCID mice are immunodeficient by definition — they lack the immune function whose interaction with MSCs is the entire question. Testing an immunomodulatory agent for tumour promotion in an animal with no functioning adaptive immunity does not answer it for a person who has one.
A veterinary review of tumour-associated risk in dogs and cats reaches a comparative conclusion — that MSCs carry lower tumour-associated risk than embryonic or induced pluripotent stem cells — while noting that "a direct confirmation of whether tumors originate from stem cells or host cells is not easily achievable" [18]. That is a reasonable statement about veterinary practice. It is not evidence about human cancer survivors, and its nude-mouse reassurance refers to the same study cited above rather than to an independent dataset.
What We Offer, and What We Do Not
We do not offer stem cell, exosome or NK/NKT therapy for cancer recurrence prevention or immune surveillance. There is no evidence base for it, the mechanism argues against it, and the reader it would be sold to is among the most vulnerable in medicine.
For survivors in documented remission who are interested in regenerative treatment for a separate condition — an orthopaedic problem, for instance — we assess case by case, and we require:
- Documented remission, minimum 6 months from completion of treatment
- Written clearance from your oncology team, who must know exactly what is proposed
- A frank discussion of everything in the safety section above, including the immunosuppression and the infection risk
- No interruption to your surveillance schedule, ever
This protocol is not appropriate for: anyone with active or uncontrolled cancer · anyone currently receiving chemotherapy or radiotherapy · anyone with severely compromised bone-marrow function · anyone seeking cancer treatment · anyone hoping to reduce their recurrence risk, because it will not.
Fear of Recurrence Is Real, and It Has Real Treatments
Fear of cancer recurrence is one of the most common and most persistent unmet needs among survivors, documented in a systematic review and individual-participant-data meta-analysis [12]. It is not irrational, it does not indicate weakness, and it does not resolve on its own.
⚠️ It also makes survivors a target. A frightened person with money and no control is the ideal customer for an unevidenced product, and the anxiety itself is often what the product is sold against. We would rather say that plainly than benefit from it.
What helps, on the evidence: psychological therapies designed for fear of recurrence · structured exercise, which improves anxiety and depressive symptoms in survivors [10]· a clear written survivorship care plan, so that you know what is being monitored and when · survivor peer support · telling your oncology team, who have seen it many times and can refer you.
The Bottom Line
Your immune system takes real time to recover after cancer treatment. That much is well documented.
Everything after that is where the honesty is required. No therapy on offer anywhere has been shown to reduce cancer recurrence by supporting immune surveillance. MSCs suppress T cells rather than activating them. The tumour-promotion concern is real and unresolved. The human safety data are reassuring on relapse and worrying on late infection.
Meanwhile the intervention with a cancer-specific mortality hazard ratio of 0.63 is walking, and the one that detects recurrence is the appointment already in your calendar.
That is not what a clinic is supposed to tell you. It is what the evidence says.